Immunotherapy for prostate cancer

被引：13

作者：

Fong L. ^{[1
]}

Small E.J. ^{[1
]}

机构：

[1] University of California, San Francisco, San Francisco, CA 94143-0511

来源：

Current Oncology Reports | 2007年 / 9卷 / 3期

关键词：

Prostate Cancer; Advanced Prostate Cancer; Prostatic Acid Phosphatase; Prostate Stem Cell Antigen; Provenge;

D O I：

10.1007/s11912-007-0026-z

中图分类号：

学科分类号：

摘要：

Whereas androgen deprivation and chemotherapy have become the cornerstone of therapy for advanced prostate cancer, novel therapies are being developed that may expand upon currently available treatments. The identification of antigens expressed by prostate tissue and/or prostate cancer that are recognized by T cells or antibodies creates opportunities to develop novel immunotherapeutic approaches including tumor vaccines. Proteins expressed in prostate cancer - including prostate-specific antigen, prostatic acid phosphatase, and prostate membrane antigen - have been used as immunologic targets for immunotherapy. Moreover, innovations in cancer genomics and proteomics also will aid in the identification of immunologic targets. Emerging trials have demonstrated that immunotherapy may generate not only immune responses in patients but also clinical responses. Future studies will be directed at capitalizing on these findings. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：226 / 233

页数：7